Multi-Cancer Detection
One blood test. Early signals across 10 cancers.
You have built a life worth protecting. The Multi-Cancer Detection by Guardant looks for early cancer signals from a single blood draw, so you can act with the same foresight you bring to everything else.
Bladder
More common with age; early changes are often silent, so timely detection matters.
Breast
One of the most common cancers in women; highly treatable when found early.
Colorectal
Usually develops silently; screening catches it before it spreads.
Esophageal
Often advances without clear symptoms; finding it sooner widens treatment options.
Stomach
Often linked to lifestyle and viral factors; early detection improves survival.
Pancreatic
Difficult to detect until late; early DNA signals are crucial.
Lung
Often symptomless until advanced; early detection saves lives.
Liver
Can develop quietly long before symptoms appear; early awareness helps.
Ovarian
Symptoms are often vague and easy to miss; early detection is challenging but important.
Prostate
One of the most common cancers in men; often slow-growing, so monitoring matters.
WHAT'S INCLUDED
10 Cancers. One Test.
Together, these 10 cancers account for around two-thirds of all cancer-related deaths.
2 in 3
cancer deaths come from these 10 types
Most
have no routine screening pathway today
45+
where the majority of cancers occur
The screening gap
Most cancers have no routine screening.
Many cancers are found only after symptoms appear. The Multi-Cancer Detection by Guardant is designed to surface signals earlier, including for cancers not covered by standard screening.
What sets Multi-Cancer Detection apart: when a signal is detected, the test gives a primary and secondary prediction of where in the body the cancer may have originated, helping guide next steps.
Step 01
Blood Draw
One 10 ml sample collected at PROTOCOL clinics.
Step 02
cfDNA extraction
Cell-free DNA is extracted from the sample.
Step 03
Methylation analysis
Patterns analysed through proprietary bioinformatics.
Step 04
Results
If positive, a Cancer Signal of Origin prediction.
HOW IT WORKS
Simple. Precise. Powerful.
What is cell-free DNA?
Cells release small amounts of DNA into the bloodstream. Cancer cells, if present, also release circulating tumour DNA. Multi-Cancer Detection reads the methylation patterns that distinguish one from the other.
What is DNA methylation?
Methylation is a natural chemical tag on DNA that can switch genes on or off. In cancer cells these tags differ, and the pattern can also hint at where a cancer may have started.
The science
Advanced science behind a simple blood draw.
74%
sensitivity for the 6 most aggressive cancers
99%
specificity, a 1% false positive rate
93%
Cancer Signal of Origin accuracy
60%
overall sensitivity across all 10 cancers
Validated in a study presented at the 2025 ASCO Annual Meeting. Selected for the US National Cancer Institute Vanguard study.
Clinically validated
Backed by over 1 million oncology blood samples tested and more than 600 peer-reviewed publications.
Clinically validated
Who should consider Multi-Cancer Detection.
You are 40 years or older
You take a proactive approach to preventive health
You have no known diagnosis of cancer
You haven't reviewed your screening plan recently
We’re Here For You, In-Person
Consult with our medical team in person at 71 Robinson Road or virtually from anywhere — flexible, convenient, and always human.
The Guardant Multi-Cancer Detection test is a laboratory developed test for individuals aged 40 or older without a known diagnosis of cancer. It is intended to complement, not replace, guideline-recommended cancer screening. A negative result does not eliminate the possibility that cancer is present or will occur in the future, and individuals should continue to participate in age-appropriate, guideline-directed screening. A positive result requires confirmatory diagnostic evaluation as directed by a qualified healthcare provider. Results should be interpreted in the context of other clinical information by a qualified medical professional.